Skip to main content

Advertisement

Table 2 Discontinuation of adjuvant hormone therapy and breast cancer events in women diagnosed with breast cancer in Stockholm, Sweden, 2001–2008. (A) Screening non-participants vs participants, (B) screening non-participants vs participants diagnosed with screen-detected cancers, and (C) screening non-participants vs participants diagnosed with interval cancers

From: Discontinuation of adjuvant hormone therapy among breast cancer patients not previously attending mammography screening

  Discontinuation of adjuvant hormone therapy, no. (%) Multivariable-adjusted, HRa (95% CIs) Breast cancer events, no. (%) Multivariable-adjusted, HRa (95% CIs)
  No Yes No Yes
(A) Non-participants vs participants
 Participants 822 (50.5) 805 (49.5) 1.00 (reference) 3449 (83.0) 707 (17.0) 1.00 (reference)
 Non-participants 146 (43.1) 193 (56.9) 1.30 (1.11–1.53) 719 (76.3) 223 (23.7) 1.22 (1.05–1.42)
(B) Non-participants vs participants (screen-detected cancers)
 Participants (screen-detected cancers) 615 (50.1) 612 (49.9) 1.00 (reference) 2523 (85.5) 427 (14.5) 1.00 (reference)
 Non-participants 146 (43.1) 193 (56.9) 1.31 (1.10–1.54) 719 (76.3) 223 (23.7) 1.32 (1.12–1.57)
(C) Non-participants vs participants (interval cancers)
 Participants (interval cancers) 207 (51.8) 193 (48.2) 1.00 (reference) 926 (76.8) 280 (23.2) 1.00 (reference)
 Non-participants 146 (43.1) 193 (56.9) 1.25 (1.02–1.53) 719 (76.3) 223 (23.7) 1.05 (0.88–1.25)
  1. aHazard ratio (HR) and 95% confidence intervals (95% CIs) adjusted for age, country of birth, marital status, tumor size, lymph node involvement, estrogen receptor status, progesterone receptor status, and grade